1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amgen NSCLC Data Could Give Lumakras Boost As Competition Looms

 
• By Alaric DeArment

Mirati’s adagrasib is expected to win an FDA lung cancer nod, while also showing better data in pancreatic and colorectal cancer, making it more important for Lumakras to show strength in NSCLC.

Amgen announced longer-term data for Lumakras in NSCLC • Source: Alamy

Amgen, Inc. KRAS inhibitor Lumakras (sotorasib)’s market position stands to gain from two-year follow-up data from the company’s pivotal study in non-small cell lung cancer showing continued benefit on survival. Longer-term survival data could help bolster Amgen’s commercial case for its drug as it gears up for potentially stiff competition from Mirati Therapeutics, Inc.’s adagrasib, a competing drug in the same class that is widely expected to get US Food and Drug Administration approval and has shown better data than Lumakras in two other key KRAS-mutated cancers.

Amgen presented two-year follow-up data from the Phase I/II CodeBreaK 100 study in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.